会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Transcriptional co-repressor that interacts with nuclear hormone receptors and uses therefor
    • 与核激素受体相互作用的转录共同抑制因子及其用途
    • US06551773B1
    • 2003-04-22
    • US09337384
    • 1999-06-21
    • Ronald M. EvansJ. Don Chen
    • Ronald M. EvansJ. Don Chen
    • C12Q100
    • C07K14/4703G01N33/74G01N2500/00
    • In accordance with the present invention, there are provided novel receptor interacting factors, referred to herein as “SMRT”, i.e., a silencing mediator (co-repressor) for retinoic acid receptor (RAR) and thyroid hormone receptor (TR). SMRT is a novel protein whose association with RAR and TR both in solution and on DNA response elements is destabilized by ligand. The interaction of SMRT with mutant receptors correlates with the transcriptional silencing activities of receptors. In vivo, SMRT functions as a potent co-repressor. A GAL4 DNA binding domain (DBD) fusion of SMRT behaves as a frank repressor of a GAL4-dependent reporter. Together, these data identify a novel class of cofactor which is believed to represent an important mediator of hormone action.
    • 根据本发明,提供了新颖的受体相互作用因子,本文称为“SMRT”,即视黄酸受体(RAR)和甲状腺激素受体(TR)的沉默介质(共抑制因子)。 SMRT是一种新的蛋白质,其与溶液中的RAR和TR在DNA响应元件上的配体不稳定。 SMRT与突变体受体的相互作用与受体的转录沉默活性相关。 在体内,SMRT作为一种有效的共抑制剂。 SMRT的GAL4 DNA结合结构域(DBD)融合作为GAL4依赖性记录的坦率阻遏物。 在一起,这些数据确定了一类新的辅因子,被认为代表激素作用的重要介质。
    • 2. 发明授权
    • SMRT co-repressors, transcriptional co-repressors that interact with nuclear hormone receptors
    • SMRT共同抑制因子,与核激素受体相互作用的转录共抑制因子
    • US07314747B1
    • 2008-01-01
    • US09522753
    • 2000-03-10
    • Ronald M. EvansJ. Don ChenPeter OrdentlichMichael R. Downes
    • Ronald M. EvansJ. Don ChenPeter OrdentlichMichael R. Downes
    • C12N1/15C12N5/10C12N15/00C07H21/04
    • C07K14/4703G01N33/74G01N2500/00
    • The present invention relates to isolated polynucleotides encoding a family of silencing mediators of retinoic acid and thyroid hormone receptor (SMRT) isoforms, including vertebrate and invertebrate isoforms thereof. The invention also relates to polypeptide SMRT co-repressors encoded by invention SMRT polynucleotides, and to peptide portions thereof that can modulate transcriptional potential of a nuclear receptor. In addition, the invention relates to chimeric molecules and to complexes containing a SMRT co-repressor or peptide portion thereof, to antibodies that specifically bind such compositions, and to methods for identifying an agent that modulates the repressor potential of a SMRT co-repressor. The invention also provides methods for identifying an agent that modulates a function of a SMRT co-repressor; for modulating the transcriptional potential of a nuclear receptor in a cell using the compositions of the invention; and for identifying a molecule that interacts specifically with a SMRT co-repressor.
    • 本发明涉及编码维甲酸和甲状腺激素受体(SMRT)同种型的沉默介导家族的分离多核苷酸,包括脊椎动物和无脊椎动物同种型。 本发明还涉及由本发明的SMRT多核苷酸编码的多肽SMRT共抑制子及其可调节核受体的转录潜力的肽部分。 此外,本发明涉及嵌合分子和含有SMRT共抑制子或其肽部分的复合物与特异性结合该组合物的抗体以及用于鉴定调节SMRT共抑制因子的阻遏物潜力的试剂的方法。 本发明还提供了用于鉴定调节SMRT共抑制子功能的试剂的方法; 用于使用本发明的组合物调节细胞中核受体的转录电位; 并用于鉴定与SMRT共抑制子特异性相互作用的分子。
    • 3. 发明授权
    • Transcriptional co-repressor that interacts with nuclear hormone receptors and uses therefor
    • 与核激素受体相互作用的转录共同抑制因子及其用途
    • US07270955B2
    • 2007-09-18
    • US10351750
    • 2003-01-23
    • Ronald M. EvansJ. Don Chen
    • Ronald M. EvansJ. Don Chen
    • C12Q1/68G01N33/567C12N15/36
    • C07K14/4703G01N33/74G01N2500/00
    • In accordance with the present invention, there are provide novel receptor interacting factors, referred to herein as “SMRT”, i.e., a silencing mediator (co-repressor) for retinoic acid receptor (RAR) and thyroid hormone receptor (TR). SMRT is a novel protein whose association with RAR and TR both in solution and on DNA response elements is destabilized by ligand. The interaction of SMRT with mutant receptors correlates with the transcriptional silencing activities of receptors. In vivo, SMRT functions as a potent co-repressor. A GAL4 DNA binding domain (DBD) fusion of SMRT behaves as a frank repressor of a GAL4-dependent reporter. Together, these data identify a novel class of cofactor which is believed to represent an important mediator of hormone action.
    • 根据本发明,提供了新的受体相互作用因子,本文称为“SMRT”,即视黄酸受体(RAR)和甲状腺激素受体(TR)的沉默介质(共抑制因子)。 SMRT是一种新的蛋白质,其与溶液中的RAR和TR在DNA响应元件上的配体不稳定。 SMRT与突变体受体的相互作用与受体的转录沉默活性相关。 在体内,SMRT作为一种有效的共抑制剂。 SMRT的GAL4 DNA结合结构域(DBD)融合作为GAL4依赖性记录的坦率阻遏物。 在一起,这些数据确定了一类新的辅因子,被认为代表激素作用的重要介质。
    • 4. 发明授权
    • Transcriptional co-repressor that interacts with nuclear hormone receptors
    • 与核激素受体相互作用的转录共同抑制因子
    • US06489441B1
    • 2002-12-03
    • US08522726
    • 1995-09-01
    • Ronald M. EvansJ. Don Chen
    • Ronald M. EvansJ. Don Chen
    • C07K14435
    • C07K14/4703G01N33/74G01N2500/00
    • In accordance with the present invention, there are provided novel receptor interacting factors, referred to herein as “SMRT”, i.e., a silencing mediator (co-repressor) for retinoic acid receptor (RAR) and thyroid hormone receptor (TR). SMRT is a novel protein whose association with RAR and TR both in solution and on DNA response elements is destabilized by ligand. The interaction of SMRT with mutant receptors correlates with the transcriptional silencing activities of receptors. In vivo, SMRT functions as a potent co-repressor. A GAL4 DNA binding domain (DBD) fusion of SMRT behaves as a frank repressor of a GAL4-dependent reporter. Together, these data identify a novel class of cofactor which is believed to represent an important mediator of hormone action.
    • 根据本发明,提供了新颖的受体相互作用因子,本文称为“SMRT”,即视黄酸受体(RAR)和甲状腺激素受体(TR)的沉默介质(共抑制因子)。 SMRT是一种新的蛋白质,其与溶液中的RAR和TR在DNA响应元件上的配体不稳定。 SMRT与突变体受体的相互作用与受体的转录沉默活性相关。 在体内,SMRT作为一种有效的共抑制剂。 SMRT的GAL4 DNA结合结构域(DBD)融合作为GAL4依赖性记录的坦率阻遏物。 在一起,这些数据确定了一类新的辅因子,被认为代表激素作用的重要介质。